Shares of biotech firm Nektar Therapeutics collapsed after the company revealed in an earnings call that there had been manufacturing issues in two batches of ...
View full coverage on Google NewsNektar Therapeutics Stock Plunges on Earnings, Disclosure of Drug Trial Issues - Barron's
Read More
Bagikan Berita Ini
Related Posts :
How A Secret Tax Dodge Is Creating Buyout Billionaires By The Dozen - Forbes- Tesla Chair Robyn Denholm on Musk: ‘I Don’t Expect Normalcy in That Environment’ - Fortune
- Zuckerberg won't give Congress what they're looking for on Wednesday - CNBC
- Finnair’s success reveals flight shame isn't an option for many - Quartzy
- Johnson & Johnson: Yield Still Not Worth The Legal Risk - Seeking Alpha
0 Response to "Nektar Therapeutics Stock Plunges on Earnings, Disclosure of Drug Trial Issues - Barron's"
Post a Comment